Phagelux lands tens of millions of yuan for phage-based biopesticides

What's the deal? Phagelux, a developer of antimicrobial products built on bacteriophages and other biological agents, has completed a strategic funding round worth tens of millions of yuan, announced in August 2026.

What's the endgame? The company creates novel antimicrobial solutions across four areas: crop science, animal health, food safety, and feed additives. Its work centres on phages and related enabling technologies.

What's the money for? Phagelux will expand production capacity for phage-based biopesticides. It also plans to advance registration and marketing of its crop-protection pipeline, and to keep iterating on its core technology.

The signal: The round points to growing investor interest in biological alternatives to conventional chemical pesticides, as agriculture looks for tools that fight pathogens without adding synthetic compounds.

Image credit: aqua.mech